1. Product Overview
2. Research Methodology
3. Impact of COVID-19
on Levofloxacin Market
4. Executive Summary
5. Manufacturing
Levofloxacin
5.1.
Raw Material
5.2.
Machinery
5.3.
Manufacturing Methods
5.4.
Contact Details of Machinery & Raw Material Suppliers
6. Pharmacodynamic
Overview of Levofloxacin
6.1.
Mechanism of Action
6.2.
Absorption
6.3.
Volume of Distribution
6.4.
Protein Binding
6.5.
Metabolism
6.6.
Route of Elimination
6.7.
Half-Life
6.8.
Clearance
6.9.
Toxicity
7. India Levofloxacin
Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value &
Volume
7.2.
Market Share & Forecast
7.2.1. By Strength (250 mg
Tablets, 500 mg Tablets, 750 mg Tablets)
7.2.2. By Application
(Pneumonia, Skin Infection, Kidney Infection, Bladder Infection, Others)
7.2.3. By Form (Tablet,
Capsule, Injection)
7.2.4. By Route of
Administration (Oral v/s Intravenous)
7.2.5. By Source (In-house
v/s Contract Manufacturing Organizations)
7.2.6. By Distribution
Channel (Online v/s Offline)
7.2.7. By End User (Adult
v/s Paediatric)
7.2.8. By Region (North,
East, South, West)
7.2.9. By Company
7.3.
Product Market Map
8.
Market Dynamics
8.1.
Drivers/Opportunities
8.2.
Challenges/Restraints
9.
Market Trends & Developments
10.
Policy & Regulatory Landscape
10.1.
Custom Duty & Taxes
10.2.
Government Subsidy & Benefits
10.3.
Relevant Policies & Regulations (GMP, USFDA, WHO
Certifications)
11.
Import & Export Analysis
12.
Pricing Analysis
13.
India Economic Profile
14.
Competitive Landscape
14.1.
Company Profiles
14.1.1. Dr. Reddy’s Laboratories
Ltd.
14.1.1.1. Company Brief
14.1.1.2. Production Plants
& Capacity (If Available)
14.1.1.3. Financials (If
Available)
14.1.1.4. Captive Consumption
Vs Merchant Sale
14.1.1.5. Current & Future
Plans
14.1.2. Aden Healthcare Pvt.
Ltd.
14.1.3. Allenge India
Pharmaceuticals Pvt. Ltd.
14.1.4. Alna Biotech Pvt.
Ltd.
14.1.5. Bestochem
Formulations India Ltd.
14.1.6. Glenmark
Pharmaceuticals Ltd.
14.1.7. Lupin Ltd.
14.1.8. Cadila Healthcare
Ltd.
14.1.9. Valentis Pharma Pvt.
Ltd.
14.1.10.
Pax Healthcare Pvt. Ltd.
15.
Strategic Recommendations
About Us &
Disclaimer